BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

736 related articles for article (PubMed ID: 15163299)

  • 1. The role of bisphosphonates in breast and prostate cancers.
    Brown JE; Neville-Webbe H; Coleman RE
    Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
    Coleman RE
    Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the role of bisphosphonates in metastatic disease.
    Ross JR; Saunders Y; Edmonds PM; Patel S; Wonderling D; Normand C; Broadley K
    Health Technol Assess; 2004; 8(4):1-176. PubMed ID: 14960258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K; Plosker GL
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "The use of bisphosphonates to treat skeletal complications in solid tumours".
    D'Oronzo S; Wood S; Brown JE
    Bone; 2021 Jun; 147():115907. PubMed ID: 33676057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
    Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
    Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of bone metastases in breast cancer.
    Lipton A
    Curr Treat Options Oncol; 2005 Mar; 6(2):161-71. PubMed ID: 15717997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates in breast cancer.
    Coleman RE
    Ann Oncol; 2005 May; 16(5):687-95. PubMed ID: 15802276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward new horizons: the future of bisphosphonate therapy.
    Lipton A
    Oncologist; 2004; 9 Suppl 4():38-47. PubMed ID: 15459428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bisphosphonates and bone metastases].
    Lortholary A; Jadaud E; Berthaud P
    Bull Cancer; 1999 Sep; 86(9):732-8. PubMed ID: 10519966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of bisphosphonates in hormone-refractory prostate cancer.
    Saad F; Karakiewicz P; Perrotte P
    World J Urol; 2005 Feb; 23(1):14-8. PubMed ID: 15666171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
    Harvey HA
    Semin Oncol; 2004 Dec; 31(6 Suppl 12):23-30. PubMed ID: 15719598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates for advanced prostate cancer.
    Yuen KK; Shelley M; Sze WM; Wilt T; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; (4):CD006250. PubMed ID: 17054286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
    Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
    Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
    Gordon DH
    Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.